Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis abandons...

    Novartis abandons effort for U.S. approval of biosimilar rituximab

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-03T09:10:14+05:30  |  Updated On 3 Nov 2018 9:10 AM IST
    Novartis abandons effort for U.S. approval of biosimilar rituximab
    According to analysts, Rituxan, a monoclonal antibody used in non-Hodgkin's lymphoma and rheumatoid arthritis, had more than $4 billion in sales in the United States in 2016.

    New Delhi: Novartis International AG has announced that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab, a medication used to treat certain cancer and rheumatoid arthritis.


    The decision comes after the U.S. Food and Drug Administration(FDA) sought additional information to support the company's application for the drug, which is approved already in the EU, Switzerland, Japan and Australia, the company said in a statement.

    "We are disappointed to have to make this decision and stand behind the safety, efficacy and quality of our medicine," said Stefan Hendriks, global head of biopharmaceuticals at Sandoz.

    Rituximab is a biosimilar drug referencing a Roche Holding AG medication marketed as Rituxan in the United States, Japan and Canada and as MabThera elsewhere. According to analysts, Rituxan, a monoclonal antibody used in non-Hodgkin's lymphoma and rheumatoid arthritis, had more than $4 billion in sales in the United States in 2016.

    A biosimilar is a biologic drug that is virtually identical to the reference product.

    An FDA committee in October recommended approval of Truxima, another biosimilar for rituximab, from South Korea's Celltrion Inc and Israel's Teva Pharmaceutical Industries Ltd. Approval is expected in late November or December.

    Sandoz said it is committed to a robust biosimilar portfolio. It has seven approved biosimilars worldwide, three of which are approved in the United States.

    Sandoz received a complete response letter from the U.S. FDA - a communication that tells a company that its application cannot be approved in its current form - for biosimilar rituximab on May 2.
    biosimilarCelltrion IncFDAnon-Hodgkin's lymphomaNovartisrheumatoid arthritisRituximabStefan HendriksTeva PharmaTruximaU.S. approvalU.S. Food and Drug AdministrationUSFDA

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok